Emerald Health Pharmaceuticals to Present at Sachs European Life Sciences CEO Forum and Exhibition

SAN DIEGO, CA / ACCESSWIRE / February 21, 2018 / Emerald Health Pharmaceuticals Inc. (EHP), which is developing medicines based on cannabinoid science, announced today that Dr. Jim DeMesa, CEO, will participate in a panel on neuroscience therapies and present an overview of the company at the 11th Annual European Life Sciences CEO Forum and Exhibition on February 26, 2018. The conference is being held at the Hilton Zurich Airport Hotel in Switzerland.

Panel: Neuroscience II – Advanced Therapies and Diagnostics

12:15 PM CET

Presentation:

2:30 PM CET

PR Track B Room Panorama A

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of inflammatory, autoimmune, metabolic, neurodegenerative, and fibrotic diseases. The company has two families of new chemical entities, based on cannabidiol, CBD, and cannabigerol, CBG, that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. The company is advancing preclinical development with the intent to launch a Phase 1 clinical study in 2018.

For more information, visit www.emeraldpharma.life or contact info@emeraldpharma.life.

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA.

SOURCE: Emerald Health Pharmaceuticals Inc.

ReleaseID: 489839